Skip to content

Launching our low cost patient access programme

12 March 2020

Lyphe, has today launched a patient registry for up to 5,000 patients. The launch follows a recent policy change allowing bulk supply to be imported and held in the UK.

The TMCC Access Programme will deliver:

  • a reliable and quicker route for patients to access their medicines
  • reduced clinician consultancy fees, and
  • standardised, low-cost prescription plans

The registry will collect real world data so that a body of evidence of quality-of-life and other patient related outcomes can be collected and provided to government groups and the NHS. This will give further reassurance of safety and efficacy when patients use medical cannabis. Patients will finally see the speed of delivery and consistency of medicines along with the realistic pricing that is to be expected, while recording critical data that will help secure an eventual NHS pathway for patients.

Hannah Deacon, mother of child epilepsy sufferer, Alfie Dingley, and long term patient advocate, said:

“It’s been a year since the rescheduling and I see first-hand that there remains a lot of families unnecessarily suffering. The recent change permitting bulk imports is an important step but there is still a long road ahead. This initiative by Lyphe will offer many patients a lifeline by making it substantially easier, quicker and vastly reducing the costs.”

According to a recently published YouGov poll 1.4 million Britons are using street cannabis to treat chronic and medically-diagnosed conditions, which demonstrates the extraordinary lengths patients are having to go to, when many of these patients should be receiving medical cannabis through the legal medical channels.

Speaking about the launch of the new patient access programme, Chief Medical Officer, Prof. Mike Barnes said:

“The TMCC Access Programme breaks down one of the biggest hurdles for patients in getting access to affordable, safe treatments prescribed to patients by experts in a clinical and legal setting.”

Prof. Barnes added:

“The collection of a body of data is of critical importance in building up the data points necessary to demonstrate the efficacy of medical cannabis for a multitude of conditions.”

Gathering of real world data on patients will be anonymised, and there will be a focus on patients suffering with: spasticity, pain, anxiety, or with neurological conditions. Whether the patient is entitled to a prescription will be down to the discretion of the patient’s clinician. In order to be approved for the registry, patients can sign up now by visiting here.

Author: Bojan
Author page

Bojan Ambrus, Head of Marketing & Digital Product at Lyphe Group, is a data-driven growth marketing professional with over 15 years of rich experience. His background includes roles such as Head of Marketing at and growth marketing roles in various enterprises, startups, and scale-ups. His expertise in building and positioning businesses is particularly valuable in the cannabis sector, where he navigates its complexities and regulatory challenges. His strategic marketing insights make Bojan a key player in shaping Lyphe Group's marketing and digital product strategies.

Latest posts

Become a patient today

Ready to start your journey?

Check if you are eligible
Start your journey in getting treated with medical cannabis
Get Started
Speak to an advisor
Free appointment with our expert Patient Advisor
Speak to an advisor